Indaptus Therapeutics, Inc.INDP
Price (close)
$4.00
Market cap
$533.0M
P/E
—
Revenue (TTM)
—
Net income
-$15.4M
Dividend yield
—
1-year total return
22.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Indaptus Therapeutics, Inc. does.
are a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy.
We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation
of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$3.6M | -$7.7M | -$14.3M | -$15.4M | -$15.0M | -$20.8M |
| Free cash flow | — | -$11.3M | — | — | — | — |
More on INDP.
- Indaptus Therapeutics, Inc. summary
- Indaptus Therapeutics, Inc. financial statements
- Indaptus Therapeutics, Inc. key metrics
- Indaptus Therapeutics, Inc. health scores and style box
- Indaptus Therapeutics, Inc. earnings
- Indaptus Therapeutics, Inc. dividends
- Indaptus Therapeutics, Inc. valuation
- Indaptus Therapeutics, Inc. ownership and insiders
- Indaptus Therapeutics, Inc. peers
Figures from Indaptus Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.